Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12

Journal of Virology

Volumn 86, Issue 9, 2012, Pages 5304-5313

  Markert, James M ^a,b,c,d   Cody, James J ^b   Parker, Jacqueline N ^b   Coleman, Jennifer M ^a   Price, Kathleen H ^b   Kern, Earl R ^b,c   Quenelle, Debra C ^b   Lakeman, Alfred D ^b   Schoeb, Trenton R ^e   Palmer, Cheryl A ^a   Cartner, Samuel C ^e   Gillespie, G Yancey ^a,c,d   Whitleya, Richard J ^a,b,c,f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; INTERLEUKIN 12; M 002; ONCOLYTIC HERPES VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AOTUS NANCYMAE; ARTICLE; BRAIN TUMOR; CLINICAL ASSESSMENT; CYTOKINE PRODUCTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRONTAL LOBE; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS 1; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS MUTANT;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; AOTIDAE; BRAIN; CELL LINE; CERCOPITHECUS AETHIOPS; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; INTERLEUKIN-12; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, SCID; SIMPLEXVIRUS; SURVIVAL ANALYSIS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

AOTUS NANCYMAAE; HUMAN HERPESVIRUS 1; MURINAE; MUS; PRIMATES; SIMPLEXVIRUS;

EID: 84861313680     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06998-11     Document Type: Article

References (59)

1. Aghi M, Rabkin S, Martuza RL. 2006. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J. Natl. Cancer Inst. 98:38-50.
2. Aghi MK, Liu TC, Rabkin S, Martuza RL. 2009. Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol. Ther. 17:51-56.
3. Andreansky S, et al. 1998. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5:121-130.
4. Andreansky SS, et al. 1996. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl. Acad. Sci. U. S. A. 93:11313-11318.
5. Baringer JR, Pisani P. 1994. Herpes simplex virus genomes in human nervous system tissue analyzed by polymerase chain reaction. Ann. Neurol. 36:823-829.
6. Carlson BL, et al. 2009. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int. J. Radiat. Oncol. Biol. Phys. 75:212-219.
7. Chambers R, et al. 1995. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. U. S. A. 92:1411-1415.
8. Chou J, Kern ER, Whitley RJ, Roizman B. 1990. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250:1262-1266.
9. Colombo MP, Trinchieri G. 2002. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13:155-168.
10. Del Vecchio M, et al. 2007. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13:4677-4685.
11. Giannini C, et al. 2005. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 7:164-176.
12. Harrow S, et al. 2004. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther. 11:1648-1658.
13. Hellums EK, et al. 2005. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol. 7:213-224.
14. Hunter WD, et al. 1999. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol. 73:6319-6326.
15. Huszthy PC, et al. 2008. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma. Clin. Cancer Res. 14:1571-1580.
16. Huszthy PC, et al. 2010. Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment. Gene Ther. 17:202-216.
17. Jenkins FJ, Roizman B. 1986. Herpes simplex virus 1 recombinants with noninverting genomes frozen in different isomeric arrangements are capable of independent replication. J. Virol. 59:494-499.
18. Katzin DS, Connor JD, Wilson LA, Sexton RS. 1967. Experimental herpes simplex infection in the owl monkey. Proc. Soc. Exp. Biol. Med. 125:391-398.
19. Kesari S, et al. 1995. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest. 73:636-648.
20. Kesari S, Lee VM, Brown SM, Trojanowski JQ, Fraser NW. 1996. Selective vulnerability of mouse CNS neurons to latent infection with a neuroattenuated herpes simplex virus-1. J. Neurosci. 16:5644-5653.
21. Kim JJ, et al. 1999. Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFNgamma, IL-12, or IL-18 gene adjuvants. J. Med. Primatol. 28:214-223.
22. Kramm CM, et al. 1997. Therapeutic efficiency and safety of a secondgeneration replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8:2057-2068.
23. Lagunoff M, Randall G, Roizman B. 1996. Phenotypic properties of herpes simplex virus 1 containing a derepressed open reading frame P gene. J. Virol. 70:1810-1817.
24. Lasner TM, et al. 1996. Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J. Neuropathol. Exp. Neurol. 55:1259-1269.
25. Liu TC, Wakimoto H, Martuza RL, Rabkin SD. 2007. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clin. Cancer Res. 13:5897-5902.
26. MacLean AR, Mul-Fareed Robertson L, Harland J, Brown SM. 1991. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the "a" sequence. J. Gen. Virol. 72:631-639.
27. Markert JM, Malick A, Coen DM, Martuza RL. 1993. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 32:597-603.
28. Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ. 2000. Genetically engineered HSV in the treatment of glioma: a review. Rev. Med. Virol. 10:17-30.
29. Markert JM, et al. 2000. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7:867-874.
30. Markert JM, et al. 2009. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM. Mol. Ther. 17:199-207.
31. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. 1991. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-856.
32. McKay EM, McVey B, Marsden HS, Brown SM, MacLean AR. 1993. The herpes simplex virus type 1 strain 17 open reading frame RL1 encodes a polypeptide of apparent M® 37K equivalent to ICP34.5 of herpes simplex virus type 1 strain F. J. Gen. Virol. 74:2493-2497.
33. Melendez LV, Espana C, Hunt RD, Daniel MD, Garcia FG. 1969. Natural herpes simplex infection in the owl monkey (Aotus trivirgatus). Lab Anim. Care 19:38-45.
34. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. 1995. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1:938-943.
35. Mok W, Stylianopoulos T, Boucher Y, Jain RK. 2009. Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy. Clin. Cancer Res. 15:2352-2360.
36. Papanastassiou V, et al. 2002. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 9:398-406.
37. Parker JN, et al. 2000. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. U. S. A. 97:2208-2213.
38. Parker JN, Bauer DF, Cody JJ, Markert JM. 2009. Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6:558-569.
39. Post LE, Roizman B. 1981. A generalized technique for deletion of specific genes in large genomes: a gene 22 of herpes simplex virus 1 is not essential for growth. Cell 25:227-232.
40. Preusser M, et al. 2011. Current concepts and management of glioblastoma. Ann. Neurol. 70:9-21.
41. Prichard MN, et al. 1990. A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. J. Virol. Methods 28:101-106.
42. Purves FC, Longnecker RM, Leader DP, Roizman B. 1987. Herpes simplex virus 1 protein kinase is encoded by open reading frame US3, which is not essential for virus growth in cell culture. J. Virol. 61:2896-2901.
43. Pyles RB, Warnick RE, Chalk CL, Szanti BE, Parysek LM. 1997. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8:533-544.
44. Rampling R, et al. 2000. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7:859-866.
45. Sarisky RT, et al. 2003. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Arch. Virol. 148:1757-1769.
46. Sarkaria JN, et al. 2006. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res. 12:2264-2271.
47. Shah AC, Benos D, Gillespie GY, Markert JM. 2003. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neurooncol. 65:203-226.
48. Shah AC, et al. 2006. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. J. Virol. 80:7308-7315.
49. Stupp R, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:987-996.
50. Stupp R, et al. 2009. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459-466.
51. Tahara H, Lotze MT. 1995. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther. 2:96-106.
52. Todo T, Rabkin SD, Chahlavi A, Martuza RL. 1999. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum. Gene Ther. 10:2869-2878.
53. Todo T, et al. 1999. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther. 10:2741-2755.
54. Todo T, et al. 2000. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol. Ther. 2:588-595.
55. Todo T, Rabkin SD, Martuza RL. 2000. Evaluation of ganciclovirmediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther. 7:939-946.
56. Todo T. 2008. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh. Migr. 2:208-213.
57. Williams-Aziz SL, et al. 2005. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother. 49:3724-3733.
58. Wong RJ, et al. 2004. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin. Cancer Res. 10:4509-4516.
59. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. 1995. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55:4752-4756.